BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...disease. Orencia is a CTLA-4 Ig fusion protein that blocks the costimulatory ligands CD80 and CD86...
BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

...to deplete activated dendritic cells. However, other activated dendritic cell markers including CD40, CD80 and CD86...
...autoimmune therapies Nulojix belatacept and Orencia abatacept from Bristol Myers Squibb Co. (NYSE:BMY) inhibit both CD86...
...JAK-2 - Janus kinase-2 Hongjiang Li, Staff Writer Bruton's tyrosine kinase (Btk) CD83 Janus kinase-2 (JAK-2) Janus kinase-1 (JAK-1) Calcineurin CD40 CD80 (B7-1) CD86 (B7-2) CXC...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Solid checkpoint for CARs

...several immune checkpoints that inhibit the anti-tumor response, most famously PD-L1, which binds PD-1, and B7-2...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...June 12th Bristol-Myers Squibb Co. (NYSE:BMY) Orencia abatacept CTLA-4 Ig fusion protein that blocks CD86 (B7-2...
...on B cells. BLyS (BAFF; TNFSF13B); CD40L (CD40LG; CD154) - CD40 ligand; CD80 (B7-1); CD86 (B7-2...
...its fusion protein Orencia abatacept, which blocks T cell costimulation by CD80 (B7-1) and CD86 (B7-2...
BioCentury | Nov 6, 2018
Distillery Techniques

Assays and screens; biomarkers

...patterns and response to 78 of the 122 drugs, including a 17-gene signature comprising CD86 (B7-2...
...RG7204 (Compound #), R7204 (Compound #), PLX4032 (Compound #), vemurafenib (Generic) Oregon Health & Science University CD86 (B7-2) FMS-like...
BioCentury | Jan 27, 2018
Company News

FDA to review its pediatric exclusivity decision for Amgen's Sensipar

...$5.93 to $196.01 on Friday. Jennie Walters Sensipar subcutaneous Orencia Amgen Amgen Inc. Bristol-Myers Squibb Co. Johnson & Johnson Teva Pharmaceutical Industries Ltd. CD80 (B7-1) CD86...
BioCentury | Jan 11, 2018
Emerging Company Profile

Next, after T cells

...PDCD1; CD279) - Programmed cell death 1 Michael Leviten, Senior Writer AstraZeneca plc NextCure Inc. Pfizer Inc. Yale University CD80 (B7-1) CD86 (B7-2) Cancer...
BioCentury | Jul 13, 2017
Clinical News

FDA approves Orencia for psoriatic arthritis

...Squibb Co. (NYSE:BMY), New York, N.Y. Product: Orencia abatacept Business: Autoimmune Julian Zhu Orencia Bristol-Myers Squibb Co. CD80 (B7-1) CD86 (B7-2) abatacept...
BioCentury | Jul 6, 2017
Clinical News

EMA's CHMP recommends Orencia in psoriatic arthritis

...Co. (NYSE:BMY), New York, N.Y. Product: Orencia abatacept (ONO-4164IV) Business: Autoimmune Alex Himes CTLA4-Ig ONO-4164IV Orencia Bristol-Myers Squibb Co. CD80 (B7-1) CD86 (B7-2) abatacept...
BioCentury | Jun 22, 2017
Clinical News

Ono, BMS submit supplemental application in Japan for Orencia to treat JIA

...Product: Orencia abatacept (ONO-4164IV) Business: Autoimmune Chris Lieu CTLA4-Ig ONO-4164IV Orencia Bristol-Myers Squibb Co. Ono Pharmaceutical Co. Ltd. Simcere Pharmaceutical Group CD80 (B7-1) CD86 (B7-2) abatacept...
Items per page:
1 - 10 of 76